Walgreens Boots Alliance, INC 8-K filings

Walgreens Boots Alliance has completed its acquisition by Sycamore Partners, transitioning to a private entity with shareholders receiving cash and contingent rights.

Walgreens Boots Alliance, Inc. has announced a temporary blackout period for its employee retirement savings plans in anticipation of its merger with Blazing Star Parent, LLC, impacting participants' ability to manage WBA Stock Fund assets.

Walgreens Boots Alliance shareholders have overwhelmingly approved the acquisition by Sycamore Partners, with the transaction expected to close in the third or fourth quarter of calendar year 2025, leading to the company's delisting.

Walgreens Boots Alliance, Inc. has filed an 8-K to provide supplemental disclosures to its definitive proxy statement, addressing shareholder lawsuits and demand letters challenging the proposed merger with Blazing Star Parent, LLC.

Walgreens Boots Alliance reported a net loss of $175 million for the third quarter of fiscal 2025, a significant decline from prior year earnings, despite a 7.2% increase in sales to $39.0 billion, as the company progresses towards its acquisition by Sycamore Partners.

Walgreens Boots Alliance establishes a $2.5 billion accounts receivable securitization facility to repay $2.0 billion in outstanding term loans and terminate related commitments.

Walgreens Boots Alliance (WBA) has reached a settlement agreement with the Department of Justice (DOJ) to resolve claims related to opioid dispensing, agreeing to pay $300 million plus interest over six years.

Walgreens Boots Alliance (WBA) reported its fiscal 2025 second quarter results, showing a loss per share of $3.30, sales of $38.6 billion, and announced the withdrawal of its fiscal 2025 guidance due to a pending acquisition by Sycamore Partners.

Walgreens Boots Alliance enters into a definitive merger agreement with Blazing Star Parent, LLC, an affiliate of Sycamore Partners, for $11.45 per share in cash plus a divested asset proceed right.

Walgreens Boots Alliance (WBA) has entered into a definitive agreement to be acquired by Sycamore Partners for a total consideration of up to $23.7 billion, including cash and potential future payments from the monetization of VillageMD businesses.

Walgreens Boots Alliance (WBA) has reached a settlement agreement with Everly Health Solutions, formerly PWNHealth LLC, to resolve all claims related to a prior arbitration award, agreeing to pay $595 million.

Walgreens Boots Alliance faces a $988 million arbitration award after a federal court upheld a previous ruling regarding a dispute with Everly Health Solutions over COVID testing services.

Walgreens Boots Alliance stockholders approved an amendment to the 2021 Omnibus Incentive Plan, increasing the available shares by 61.5 million, and an amendment to the Certificate of Incorporation providing officer exculpation.

Walgreens Boots Alliance has announced the suspension of its quarterly cash dividend to strengthen its balance sheet and support its long-term turnaround strategy.

Walgreens Boots Alliance reported a first quarter loss per share of $0.31, but maintained its full-year adjusted EPS guidance of $1.40 to $1.80.

Walgreens Boots Alliance has reached a settlement in a shareholder derivative lawsuit, agreeing to implement corporate governance reforms and pay $750,000 in legal fees and expenses.

Walgreens Boots Alliance plans to close approximately 1,200 stores over the next three years as part of a footprint optimization program, while reporting a significant net loss for fiscal year 2024.

Walgreens Boots Alliance has successfully completed a public offering of $750 million in 8.125% notes due in 2029.

Walgreens Boots Alliance is reviewing its investment in VillageMD after the company defaulted on a $2.25 billion loan, potentially leading to a sale or restructuring.

Walgreens Boots Alliance has updated its bylaws to better align with Delaware corporate law and to clarify procedures for stockholder meetings and director nominations.

Walgreens Boots Alliance has appointed William Shrank, M.D., a healthcare strategy and policy expert, to its board of directors effective September 1, 2024.

Walgreens Boots Alliance has lowered its fiscal year 2024 adjusted EPS guidance due to a difficult operating environment and persistent pressures on the U.S. consumer.

Walgreens Boots Alliance has agreed to a $36 million settlement and corporate governance reforms to resolve a shareholder derivative lawsuit related to opioid oversight.

Walgreens Boots Alliance's Executive Vice President and President of U.S. Healthcare, John Driscoll, will retire and transition to a consulting role, effective April 8, 2024.

Walgreens Boots Alliance reported a net loss due to a substantial non-cash impairment charge related to VillageMD, while adjusted earnings per share saw a modest increase.

Walgreens Boots Alliance has announced key leadership appointments, including a new CFO and U.S. Healthcare President, as part of a broader strategy to enhance its healthcare services and drive growth.

Walgreens Boots Alliance held its 2024 Annual Meeting, electing directors and voting on several shareholder proposals, including executive compensation and social responsibility matters.